Aadi Bioscience, Inc. (AADI) Financial Statements (2024 and earlier)

Company Profile

Business Address 17383 SUNSET AVENUE
PACIFIC PALISADES, CA 90272
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:134,900151,200172,600183,000118,737129,849
Cash and cash equivalents68,16234,04639,019134,815118,737129,849
Short-term investments66,727117,128133,54148,192  
Other undisclosed cash, cash equivalents, and short-term investments112640(7)  
Receivables3,6765,5651,8622,2612,0632,708
Inventory, net of allowances, customer advances and progress billings3,4573,8031,861734727202
Inventory3,4573,8031,861734727202
Other undisclosed current assets2,8904,3623,7063,8682,8082,861
Total current assets:144,923164,930180,029189,863124,335135,620
Noncurrent Assets
Operating lease, right-of-use asset1,3491,4371,5221,5731,653518
Property, plant and equipment3,0052,225508457357101
Intangible assets, net (including goodwill)      3,743
Intangible assets, net (excluding goodwill)      3,743
Other noncurrent assets1,9512,0622,1782,2102,2912,337
Total noncurrent assets:6,3055,7244,2084,2404,3016,699
TOTAL ASSETS:151,228170,654184,237194,103128,636142,319
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,58317,34318,44122,55516,12611,347
Employee-related liabilities5,0383,854
Accounts payable2,8986,5103,5193,9203,6194,010
Accrued liabilities9,68510,83314,92213,5978,6537,337
Other undisclosed current liabilities413404394(4,664)(3,530)163
Total current liabilities:12,99617,74718,83517,89112,59611,510
Noncurrent Liabilities
Long-term debt and lease obligation:    1,3471,444424
Liabilities, other than long-term debt1,0561,1641,267 109 
Other liabilities     109 
Operating lease, liability1,0561,1641,2671,3471,444424
Other undisclosed noncurrent liabilities 5,7575,7575,7574,4105,7575,333
Total noncurrent liabilities:6,8136,9217,0247,1047,3106,181
Total liabilities:19,80924,66825,85924,99519,90617,691
Equity
Equity, attributable to parent131,419145,986158,378169,108108,730124,628
Common stock222222
Additional paid in capital367,853364,437361,689358,490283,539281,168
Accumulated other comprehensive loss(44)(32)(115)(99)  
Accumulated deficit(236,392)(218,421)(203,198)(189,285)(174,811)(156,542)
Total equity:131,419145,986158,378169,108108,730124,628
TOTAL LIABILITIES AND EQUITY:151,228170,654184,237194,103128,636142,319

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues6,2025,8675,2274,2453,4372,307
Cost of revenue
(Cost of Goods and Services Sold)
(656)(529)(222)(593)(341)(179)
Gross profit:5,5465,3385,0053,6523,0962,128
Operating expenses(25,091)(22,163)(20,477)(18,688)(21,456)(15,942)
Operating loss:(19,545)(16,825)(15,472)(15,036)(18,360)(13,814)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
1,5741,6021,550562100(43)
Interest and debt expense(58)(58)(57)(58)(58)(58)
Loss from continuing operations before equity method investments, income taxes:(18,029)(15,281)(13,979)(14,532)(18,318)(13,915)
Other undisclosed income from continuing operations before income taxes58 57585858
Loss from continuing operations before income taxes:(17,971)(15,281)(13,922)(14,474)(18,260)(13,857)
Income tax expense     (9) 
Other undisclosed income from continuing operations   9   
Loss from continuing operations:(17,971)(15,281)(13,913)(14,474)(18,269)(13,857)
Loss before gain (loss) on sale of properties:(14,474)(18,269)(13,857)
Net loss:(17,971)(15,281)(13,913)(14,474)(18,269)(13,857)
Other undisclosed net income attributable to parent  58    
Net loss available to common stockholders, diluted:(17,971)(15,223)(13,913)(14,474)(18,269)(13,857)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(17,971)(15,281)(13,913)(14,474)(18,269)(13,857)
Other comprehensive income (loss)  83 (99)  
Other undisclosed comprehensive loss   (115)   
Comprehensive loss:(17,971)(15,198)(14,028)(14,573)(18,269)(13,857)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(12)5899   
Comprehensive loss, net of tax, attributable to parent:(17,983)(15,140)(13,929)(14,573)(18,269)(13,857)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: